| Patents for A61P 21 - Drugs for disorders of the muscular or neuromuscular system (23,287) |
|---|
| 06/16/2005 | US20050130145 polynucleotides which identify and encode human secreted proteins (SECP); expression vectors, host cells, antibodies, and agonists; drug screening |
| 06/16/2005 | US20050129716 Therapeutic use of botulinum toxins types A and B |
| 06/15/2005 | EP1539934A2 Compositions comprising muscle progenitor cells and uses thereof |
| 06/15/2005 | EP1539933A2 Methods of organ regeneration |
| 06/15/2005 | EP1539769A1 Bicyclic heteroaromatic compounds as kinase inhibitors |
| 06/15/2005 | EP1539763A1 Azaindole kinase inhibitors |
| 06/15/2005 | EP1539732A1 Novel compounds |
| 06/15/2005 | EP1539701A1 Caspase inhibitors and uses thereof |
| 06/15/2005 | EP1539695A1 N-4-piperidinyl compounds as ccr5 modulators |
| 06/15/2005 | EP1539683A2 Phenol derivatives and their use as rotamase inhibitors |
| 06/15/2005 | EP1539674A1 Amino-propanol derivatives |
| 06/15/2005 | EP1539662A1 Cannabinoid receptor ligands |
| 06/15/2005 | EP1539284A2 Liquid aerosol formulations and aerosol generating devices and methods for generating aerosols |
| 06/15/2005 | EP1539169A2 Amyotrophic lateral sclerosis treatment with cyclooxygenase-2 inhibitors |
| 06/15/2005 | EP1539166A1 Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders |
| 06/15/2005 | EP1538927A1 Fruit and/or vegetable derived composition |
| 06/15/2005 | EP1538913A2 Modulation of stem and progenitor cell differentiation, assays, and uses thereof |
| 06/15/2005 | EP1345609B1 Tetrahydro-(benzo or thieno)-azepine-pyrazine and triazine derivatives as mglur 1 antagonists |
| 06/15/2005 | EP1257277B1 New drug combinations comprising a norepinephrine reuptake inhibitor and an antimuscarinic agent |
| 06/15/2005 | CN1628107A Heteroaryl alkyl piperazine derivatives as fatty acid oxidation inhibitors |
| 06/15/2005 | CN1627944A Substituted quinazolin-4-ylamine analogues as modulators of capsaicin |
| 06/15/2005 | CN1626228A Extractive from decoction of rehmannia including six elements, combination of medication, and medical use |
| 06/15/2005 | CN1626077A Treatment of nuerodegenerative diseases |
| 06/15/2005 | CN1206228C N-heterocyclic derivatives as NOS inhibitors |
| 06/15/2005 | CN1206213C N-arylsulfonyl amino acid omega amides |
| 06/14/2005 | US6906065 4-Amino-5-cyano-2-anilino-pyrimidine derivatives and their use as inhibitors of cell-cycle kinases |
| 06/14/2005 | US6906059 Administering cardioprotective amount of a benzazepin-N-acetic acid derivative for inhibiting or treating heart damage induced by a cardiotoxic medicamet in a mammal |
| 06/14/2005 | US6906053 Antiarthritic agents; antiulcer agents; osteoporosis; antiinflammatory agents; antitumor and anticancer agents |
| 06/14/2005 | US6906051 Viricides, fungicides, microbiocides, osteoporosis |
| 06/14/2005 | US6906041 Treatment of immune diseases |
| 06/14/2005 | US6905855 Isolated human drug-metabolizing proteins, nucleic acid molecules encoding human drug-metabolizing proteins, and uses thereof |
| 06/14/2005 | US6905688 Comprises therapeutic fusion proteins for diagnosis and treatment of cancers, neovascularization and autoimmune diseases |
| 06/14/2005 | CA2400318C Botulinum toxin pharmaceutical compositions |
| 06/14/2005 | CA2163122C Positive inotropic and lusitropic pyrroloquinolinone derivatives |
| 06/09/2005 | WO2005051993A1 Novel muscle growth regulator |
| 06/09/2005 | US20050124691 Alpha-aryl-N-alkylnitrones and pharmaceutical compositions containing the same |
| 06/09/2005 | US20050124689 Tocopherol enriched compositions and amelioration of inflammatory symptoms |
| 06/09/2005 | US20050124649 Deazapurines and uses thereof |
| 06/09/2005 | US20050124642 (1-Indanone)-(1,2,3,6-tetrahydropyridine) compounds |
| 06/09/2005 | US20050124631 For example, 2-amino-7-chloro-6-hydroxy-4-methylbenzothiazole; compounds that prevent the formation of polyglutamine containing protein aggregates; treatment of spinal and bulbar muscular atrophy, dentatorubal pallidoluysian atrophy, spinocerebellar ataxia, Alzheimers disease |
| 06/09/2005 | US20050124621 Novel inhibitors of kinases |
| 06/09/2005 | US20050124554 Spermidine derivatives for the treatment of chronic neurodegenerative diseases |
| 06/09/2005 | US20050124537 Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein |
| 06/09/2005 | US20050124003 Using immunoaffinity selection to isolate and propagate pluripotent stem cell populations from fetal developmental tissues; cell replacement therapies |
| 06/09/2005 | US20050123912 Nucleoprotein for use as tool in treatment, diagnosis and prevention of infection, cell proliferative, neurological, developmental, autoimmune and inflammatory disorders |
| 06/09/2005 | US20050123897 Controlling flux of penetrants across adaptable, semipermeable porous barrier by enlarging applied dose per area; drug delivery kits, patches |
| 06/09/2005 | US20050123531 Administering to the individual therapeutically effective amount of human acid alpha-glucosidase at regular interval for therapy of glycogen storage disease type II |
| 06/09/2005 | CA2547326A1 Novel muscle growth regulator |
| 06/08/2005 | EP1537863A1 Preventive therapeutic composition for muscular fatigue, pulled muscle and disease attributed thereto |
| 06/08/2005 | EP1537138A2 Receptors and membrane-associated proteins |
| 06/08/2005 | EP1537104A1 Aza-bicycloalkyl ethers and their use as alpha7-nachr agonist |
| 06/08/2005 | EP1536835A1 Liquid formulations with high concentration of human growth hormone (hgh) comprising phenol |
| 06/08/2005 | CN1205205C Sodium-hydrogen exchanger type 1 inhibitor crystals |
| 06/07/2005 | US6903187 Structural modification of clostridal neurotoxins including addition or deletion of a leucine-based motif to treat biological disorders include treating autonomic disorders, neuromuscular disorders and pain |
| 06/07/2005 | US6903131 Administering to a patient an antiangiogenesis or anticancer agent (N,N-disubstituted-3,4-diamino-2,4-dione-pyrroline derivatives for the treatment of chemokine-mediated diseases such as acute and chronic inflammatory disorders and cancer |
| 06/07/2005 | US6903127 Sexual disorders |
| 06/07/2005 | US6903115 Bipiperidine compounds |
| 06/07/2005 | US6903106 Nitrogen compounds having improved solubility, bioavailability and stability, used as sedatives, anxiolytics, anticonvulsant, and/ or muscle relaxants for prophylaxis of sleep disorders |
| 06/02/2005 | US20050119499 Cyclic hemiacetal derivative and use thereof |
| 06/02/2005 | US20050119458 Transport protein for use in identifying modulator for prevention and treatment of cell proliferative, skin and psychological disorders; anticonvulsants; insecticides; pesticides; anthelmintics |
| 06/02/2005 | US20050119450 Biodegradable polyphosphoramidates for controlled release of bioactive substances |
| 06/02/2005 | US20050119321 2-substituted-1,3-thiazole compounds |
| 06/02/2005 | US20050119277 Benzazole derivatives for the treatment of scleroderma |
| 06/02/2005 | US20050119250 Amino-derivatives as novel inhibitors of histone deacetylase |
| 06/02/2005 | US20050118715 Modulation of stem and progenitor cell differentiation, assays, and uses thereof |
| 06/02/2005 | US20050118573 Nucleic sequence and deduced protein sequence family with human endogenous retroviral motifs, and their uses |
| 06/02/2005 | US20050118242 Using testosterone; topical applying to skins |
| 06/01/2005 | EP1535065A2 Neuroprotective synergy of erythropoietin and insulin-like growth factor |
| 06/01/2005 | EP1534725A2 Compounds and methods for inhibiting selectin-mediated function |
| 06/01/2005 | EP1534687A1 Pyrimidine compounds |
| 06/01/2005 | EP1534668A1 Crystalline solid form of (2s-5z)-2-amino-7-(ethanimidoylamino)-2-methylhept-5-enoic acid |
| 06/01/2005 | EP1534666A1 Compounds for modulating the glycolosis enzyme complex and/or transaminase complex |
| 06/01/2005 | EP1534663A1 N-bridged selective androgen receptor modulators and methods of use thereof |
| 06/01/2005 | EP1534391A1 Novel piperazinyl-pyrazinone derivatives for the treatment of 5-ht2a receptor-related disorders |
| 06/01/2005 | EP1534290A2 Novel inhibitors of kinases |
| 06/01/2005 | EP1534256A2 Immunomodulation and effect on cell processes relating to serotonin family receptors and the blood-brain barrier |
| 06/01/2005 | EP1534250A2 Electrospun amorphous pharmaceutical compositions |
| 06/01/2005 | EP1404330B1 Substituted 8-arylquinoline pde4 inhibitors |
| 06/01/2005 | EP1233951B1 3,4-dihydro-(1h)quinazolin-2-one compounds as csbp/p38 kinase inhibitors |
| 06/01/2005 | EP1188754B1 Substituted pyrazole compounds |
| 06/01/2005 | EP1178977B1 Ion channel modulating agents |
| 06/01/2005 | EP1171160B1 Method and means for treating post-polio syndrome |
| 06/01/2005 | EP1062210B1 1,2-diazepane derivatives as interleukin-1beta converting enzyme inhibitors |
| 06/01/2005 | CN1622995A Receptor nucleic acids and polypeptides |
| 06/01/2005 | CN1622957A IFNAR2 mutants, their production and use |
| 06/01/2005 | CN1621526A Recombinant adeno-associated virus for prevention and cure of I-type diabetes and use thereof |
| 06/01/2005 | CN1204121C 1, 4-substituted cyclic amine derivatives or dihydro indole derivatives and medicines containing same |
| 06/01/2005 | CN1203852C Valdecoxib compositions |
| 05/31/2005 | US6900232 For therapy of tumor metastasis, solid tumor growth (neoplasia), osteoporosis, Paget's disease, humoral hypercalcemia of malignancy, osteopenia, angiogenesis, including tumor angiogenesis and lymphangiogenesis |
| 05/31/2005 | US6900214 Cyano-substituted dihydropyrimidine compounds and their use to treat diseases |
| 05/31/2005 | US6900212 Anxiolytic agents; psychological disorders; sexual disorders; eating disorders |
| 05/31/2005 | US6900043 Phosphatases which activate map kinase pathways |
| 05/26/2005 | US20050113451 7-acetamidinyl derivatives |
| 05/26/2005 | US20050113416 Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods |
| 05/26/2005 | US20050113386 Treating bipolar disorder, mania, dementia, sexual dysfunction, eating disorders, fibromyalgia |
| 05/26/2005 | US20050113370 Therapeutic substituted indazole derivatives |
| 05/26/2005 | US20050113368 eg (+-) Ethyl 3-[4-{3-(3,4-dihydro-2H-benzo[b][1,4]oxazin-4-yl)propylamino}phenyl]-2-ethoxypropanoate; antidiabetic, hypolipidemic, antiobesity and hypocholesterolemic |
| 05/26/2005 | US20050113361 Amide derivatives as NMDA receptor antagonists |
| 05/26/2005 | US20050113360 NMDA (N-methyl-D-aspartate) receptors; eg 6-(4-benzylpiperidin-1-carbonyl)-1,5-dihydro-oxazolo[4,5-f]indole-2-one |
| 05/26/2005 | US20050113359 NMDA (N-methyl-D-aspartate) receptors; eg 1-[4-(4-fluoro-benzyl)-piperidin-1-yl]-1-(6-hydroxy-1H-indole-2-yl)methanone |